JAK2 and myeloid neoplasm: Other alterations that activate JAK2, such as fusions [160,161,162,163,164,165] or amplifications [166], may also confer sensitivity to JAK2 inhibitors on the basis of clinical data in myeloid neoplasms as well as preclinical data.